Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -2.88% | -3.14% | +5.86% |
May. 09 | Earnings Flash (PRPH) PROPHASE LABS Posts Q1 Revenue $3.6M, vs. Street Est of $9.9M | MT |
May. 09 | Transcript : ProPhase Labs, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Business Summary
Number of employees: 113
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Services
56.0
%
| 108 | 88.3 % | 25 | 56.0 % | -77.06% |
Consumer Products
44.0
%
| 14 | 11.7 % | 20 | 44.0 % | +36.44% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 123 | 100.0 % | 44 | 100.0 % | -63.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Chief Operating Officer | 50 | Dec. 31 | |
Robert Morse
AUD | Comptroller/Controller/Auditor | 49 | 22-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Gleckel
BRD | Director/Board Member | 68 | 09-05-31 |
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Jason Barr
BRD | Director/Board Member | 44 | 15-05-31 |
Warren Hirsch
BRD | Director/Board Member | 66 | 19-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,019,496 | 15,745,340 ( 41.41 %) | 18,940,967 ( 49.82 %) | 41.41 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
LANTERN PHARMA INC. 5.88% | 631,195 | 5.88% | 3,446,325 $ |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.86% | 92.72M | |
-22.94% | 7.77B | |
+77.22% | 4.51B | |
+6.87% | 2.76B | |
-2.63% | 2.67B | |
-47.96% | 2.09B | |
-17.68% | 1.72B | |
-19.12% | 1.49B | |
+18.29% | 1.22B | |
-44.77% | 1.12B |
- Stock Market
- Equities
- PRPH Stock
- Company ProPhase Labs, Inc.